Soligenix SNGX

NASDAQ SNGX

$0.38 +0.00 (+0.21%)

As of: Sep 9, 2026 · 3:37 PM EDT

Key Stats

Market Cap6.00 Mn

P/E-0.59

Div. Yield0.00

Add ratio to table…

About

Soligenix, Inc. is a late stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases with unmet medical need. The company leverages proprietary platforms such as synthetic hypericin for photodynamic therapy, IDR technology for immune modulation, and ThermoVax for vaccine thermostabilization. Its pipeline includes product candidates for cutaneous T cell lymphoma, psoriasis, inflammatory diseases, and biodefense threats like ricin…

The company generates revenue primarily from government grants and contracts awarded by agencies such as the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, and the Defense Threat Reduction Agency. Additionally, it earns royalty and licensing income from partners like SciClone for its SGX942 product candidate and receives milestone payments under its license agreements. As of the filing date, Soligenix has not yet commercialized any product, so its revenue is driven by these non product sources.

The company operates through the following segments: Specialized BioTherapeutics and Public Health Solutions. These segments are defined by product area rather than geography.

Specialized BioTherapeutics: This segment develops HyBryte™ (synthetic hypericin) for cutaneous T cell lymphoma, with a completed Phase 3 FLASH study showing statistical significance and a second Phase 3 FLASH2 trial enrolling patients in December 2024 for top level results expected in the second half of 2026. It also advances SGX302 (synthetic hypericin) for psoriasis, having completed a Phase 2a study that demonstrated biological effect and clinically meaningful benefit. Additionally, the segment progresses dusquetide (SGX942) for oral mucositis in head and neck cancer and dusquetide (SGX945) for aphthous ulcers in Behçet’s disease, both supported by Phase 2 data and ongoing discussions for further development.
Public Health Solutions: This segment focuses on the RiVax ricin vaccine, which has completed Phase 1 clinical trials showing safety and immunogenicity and is being developed under the FDA Animal Rule for potential licensure. It also develops SGX943 as a therapeutic for antibiotic resistant and emerging infectious diseases, currently in preclinical stage. The segment includes vaccine programs for filoviruses such as Ebola and Marburg, and a COVID 19 vaccine candidate (CiVax), all leveraging the ThermoVax heat stabilization platform to enable thermostable formulations. Development is supported by government grant and contract funding from NIAID, BARDA, and DTRA.

Soligenix occupies a niche position in the rare disease biopharmaceutical sector, competing against larger firms while leveraging its proprietary technologies such as synthetic hypericin, IDR based dusquetide, and ThermoVax platform, which have earned orphan drug and fast track designations that provide potential market exclusivity and regulatory advantages. The company’s dermatology candidates, HyBryte™ and SGX302, differentiate themselves by using visible light activation instead of ultraviolet radiation, reducing the risk of secondary skin cancers compared with conventional PUVA therapy. In the infectious disease arena, its ThermoVax enabled vaccines aim to eliminate cold chain requirements, offering logistical and cost benefits for stockpiling against threats like ricin, Ebola, and Marburg. Management estimates potential peak sales for HyBryte™ in excess of $250 million, for SGX302 over $1 billion, for SGX942 above $500 million, and for SGX945 beyond $200 million, reflecting the size of the addressed rare disease markets.

The company serves patients with rare diseases, healthcare providers who administer its therapies, and government agencies that fund its biodefense programs. Specific licensing partners include SciClone, which holds rights to develop and commercialize SGX942 in certain Asian territories and pays royalties on net sales. Additionally, Soligenix collaborates with contract manufacturers such as Sterling Pharma Solutions for the production of synthetic hypericin used in HyBryte™ and SGX302. Its product candidates are intended for use in hospitals, outpatient clinics, and national stockpiles where they would be administered by physicians or dispensed to patients.

Investment Thesis

▲ Bull case

Soligenix's ThermoVax® platform provides a distinct competitive advantage in vaccine development, particularly for filoviruses like Bundibugyo virus, as it enables thermostable subunit vaccines that remain stable for at least 2 years at 40°C (104°F), eliminating the need for ultra-cold chain storage required by existing Ebola vaccines; this feature is critical for deployment in resource-limited endemic regions in Africa and for strategic national stockpiles, where logistical barriers have historically hampered vaccination efforts, and positions Soligenix to capture significant demand from governments and global health organizations seeking practical, scalable solutions for outbreak preparedness, especially given the ongoing Public Health Emergency of International Concern declared by WHO for the Bundibugyo outbreak in DRC and Uganda with 80 deaths and 246 suspected cases as of May 15, 2026.
The company's IDR technology platform, exemplified by dusquetide (SGX945), demonstrates compelling clinical validation in Behçet's Disease, with Phase 2a data showing a 40% improvement in ulcer area under the curve versus placebo—exceeding the 37% improvement seen with the approved drug apremilast (Otezla®)—and sustained efficacy through Week 8 despite treatment cessation at Week 4, suggesting a durable mechanism of action; this, combined with orphan drug designations from both FDA and EMA (providing 7-year and 10-year market exclusivity in the U.S. and EU, respectively), PIM designation from MHRA, and Fast Track status, creates a clear regulatory and commercial pathway for SGX945 in a global market of up to 1 million patients, where current therapies are limited by poor tolerability (e.g., apremilast's 41% diarrhea rate) and continuous dosing requirements.
Despite the futility call in the FLASH2 HyBryte™ trial for CTCL, Soligenix retains significant upside from its Specialized BioTherapeutics pipeline, as the CEO highlighted in the February 2026 letter that peak U.S. net sales for HyBryte™ could exceed $90 million annually, with a global CTCL TAM above $250 million, and the psoriasis opportunity with SGX302 could surpass $1 billion annually—figures that remain unchallenged by recent data and are supported by the drug's favorable safety profile (no systemic absorption, non-mutagenic, non-carcinogenic light source) and prior Phase 3 efficacy (49% response at 18 weeks in the first FLASH study), suggesting that the FLASH2 outcome may reflect trial design issues (e.g., patient selection or endpoint sensitivity) rather than intrinsic drug failure, especially given supportive real-world data showing 60% treatment success versus Valchlor®'s 20% in the April 2026 comparability study.
Soligenix's financial position, while modest, provides strategic flexibility: the company reported $6.0 million in cash as of March 31, 2026, with cash runway into Q2 2027, and has consistently leveraged non-dilutive funding sources—including $500K from New Jersey's NOL sales program, $2.6M FDA Orphan Products Development grant for HyBryte™ real-world studies, and ongoing NIAID, DTRA, and BARDA support for its vaccine programs—reducing reliance on equity dilution and enabling continued advancement of SGX945 and RiVax®, particularly as the Behçet's Disease program advances toward a placebo-controlled Phase 2 trial in H2 2026, which could catalyze partnership interest or acquisition value given the unmet need in a 1-million-patient global market with no approved alternatives beyond apremilast.
The filovirus vaccine platform benefits from structural tailwinds beyond the current Bundibugyo outbreak, as the ThermoVax® technology has already been validated for ricin toxin (RiVax®), Ebola, Sudan, Marburg, and COVID-19 vaccines, creating a modular, plug-and-play system where new antigens (like Bundibugyo glycoprotein) can be rapidly integrated—a fact emphasized by Dr. Lehrer's statement about "platform compatibility"—which reduces development risk and timelines, and positions Soligenix to respond swiftly to future filovirus threats or biodefense needs, especially as governments renew focus on pandemic preparedness post-COVID, with potential BARDA or DTRA contracts offering significant non-dilutive funding for advanced development and stockpiling.

Soligenix's ThermoVax® platform provides a distinct competitive advantage in vaccine development, particularly for filoviruses like Bundibugyo virus, as it enables thermostable subunit vaccines that remain stable for at least 2 years at 40°C (104°F), eliminating the need for ultra-cold chain storage required by existing Ebola vaccines; this feature is critical for deployment in resource-limited endemic regions in Africa and for strategic national stockpiles, where logistical barriers have historically hampered vaccination efforts, and positions Soligenix to capture significant demand from governments and global health organizations seeking practical, scalable solutions for outbreak preparedness, especially given the ongoing Public Health Emergency of International Concern declared by WHO for the Bundibugyo outbreak in DRC and Uganda with 80 deaths and 246 suspected cases as of May 15, 2026.
The company's IDR technology platform, exemplified by dusquetide (SGX945), demonstrates compelling clinical validation in Behçet's Disease, with Phase 2a data showing a 40% improvement in ulcer area under the curve versus placebo—exceeding the 37% improvement seen with the approved drug apremilast (Otezla®)—and sustained efficacy through Week 8 despite treatment cessation at Week 4, suggesting a durable mechanism of action; this, combined with orphan drug designations from both FDA and EMA (providing 7-year and 10-year market exclusivity in the U.S. and EU, respectively), PIM designation from MHRA, and Fast Track status, creates a clear regulatory and commercial pathway for SGX945 in a global market of up to 1 million patients, where current therapies are limited by poor tolerability (e.g., apremilast's 41% diarrhea rate) and continuous dosing requirements.
Despite the futility call in the FLASH2 HyBryte™ trial for CTCL, Soligenix retains significant upside from its Specialized BioTherapeutics pipeline, as the CEO highlighted in the February 2026 letter that peak U.S. net sales for HyBryte™ could exceed $90 million annually, with a global CTCL TAM above $250 million, and the psoriasis opportunity with SGX302 could surpass $1 billion annually—figures that remain unchallenged by recent data and are supported by the drug's favorable safety profile (no systemic absorption, non-mutagenic, non-carcinogenic light source) and prior Phase 3 efficacy (49% response at 18 weeks in the first FLASH study), suggesting that the FLASH2 outcome may reflect trial design issues (e.g., patient selection or endpoint sensitivity) rather than intrinsic drug failure, especially given supportive real-world data showing 60% treatment success versus Valchlor®'s 20% in the April 2026 comparability study.
Soligenix's financial position, while modest, provides strategic flexibility: the company reported $6.0 million in cash as of March 31, 2026, with cash runway into Q2 2027, and has consistently leveraged non-dilutive funding sources—including $500K from New Jersey's NOL sales program, $2.6M FDA Orphan Products Development grant for HyBryte™ real-world studies, and ongoing NIAID, DTRA, and BARDA support for its vaccine programs—reducing reliance on equity dilution and enabling continued advancement of SGX945 and RiVax®, particularly as the Behçet's Disease program advances toward a placebo-controlled Phase 2 trial in H2 2026, which could catalyze partnership interest or acquisition value given the unmet need in a 1-million-patient global market with no approved alternatives beyond apremilast.
The filovirus vaccine platform benefits from structural tailwinds beyond the current Bundibugyo outbreak, as the ThermoVax® technology has already been validated for ricin toxin (RiVax®), Ebola, Sudan, Marburg, and COVID-19 vaccines, creating a modular, plug-and-play system where new antigens (like Bundibugyo glycoprotein) can be rapidly integrated—a fact emphasized by Dr. Lehrer's statement about "platform compatibility"—which reduces development risk and timelines, and positions Soligenix to respond swiftly to future filovirus threats or biodefense needs, especially as governments renew focus on pandemic preparedness post-COVID, with potential BARDA or DTRA contracts offering significant non-dilutive funding for advanced development and stockpiling.

▼ Bear case

The discontinuation of the FLASH2 HyBryte™ trial for futility in April 2026 represents a material setback, as the Data Monitoring Committee's recommendation to halt the study due to lack of efficacy signal—despite 18 weeks of treatment—directly contradicts the earlier Phase 3 FLASH trial's 49% response rate and undermines the core thesis for HyBryte™ as a near-term commercial asset, especially since the company explicitly stated it will analyze data to determine why the study failed, raising concerns about patient heterogeneity, dosing adequacy, or diminishing returns with prolonged exposure, and casting doubt on the validity of prior efficacy signals in the absence of a confirmed mechanism for the discrepancy between studies.
Soligenix's financial runway is increasingly precarious, with cash declining from $7.9 million at December 31, 2025 to $6.0 million by March 31, 2026, reflecting a quarterly burn rate of approximately $1.9 million, and while management claims runway into Q2 2027, this assumes no further setbacks and ignores the likelihood of increased spending to advance SGX945 into Phase 2 or pursue M&A; the absence of any revenue streams—confirmed in both the March 31, 2026 and December 31, 2025 financial updates—means the company remains entirely dependent on external financing, which may be unavailable on acceptable terms given the HyBryte™ failure and the high-risk nature of its biodefense and rare disease pipeline, increasing the probability of a dilutive financing event or forced asset sale.
The Behçet's Disease program, while buoyed by orphan designations, faces significant commercialization hurdles: SGX945 has only demonstrated biological efficacy in a tiny Phase 2a pilot of 8 patients, with no placebo-controlled Phase 2 data yet generated, and the planned H2 2026 trial is still contingent on completing formulation work for home-use administration—a technical risk that has not been de-risked—while the global market estimate of $200 million annually assumes broad uptake in a disease where current therapy (apremilast) already fails due to tolerability issues and chronic use requirements, and there is no guarantee that dusquetide's intermittent dosing advantage will translate to real-world adherence or payer reimbursement, especially without head-to-head Phase 3 data against the incumbent.
The filovirus vaccine opportunity, despite its scientific merit, remains highly speculative and dependent on unpredictable government funding; while the ThermoVax® platform has shown thermostability and immunogenicity in preclinical models, there is no clinical data for a Bundibugyo-specific vaccine, and advancement requires "adequate funding" per Dr. Lehrer's statement, with no committed BARDA, DTRA, or NIAID contracts mentioned in the news—unlike RiVax® which has historical BARDA support—making near-term milestones uncertain, and the company's Public Health Solutions segment has historically relied on grant funding that is subject to performance requirements and renewal risk, as acknowledged in its risk factors, meaning any delay in securing new awards could stall development indefinitely.
Soligenix faces intense competitive pressures in both its rare disease and vaccine segments: in Behçet's Disease, apremilast (Otezla®) is an established, FDA-approved maintenance therapy with broad physician familiarity and payer coverage, despite its side effects, and new entrants like biosimilars or novel small molecules could emerge before SGX945 completes development; in the vaccine space, existing filovirus candidates (e.g., Merck's Ebola vaccine, Janssen's regimens) benefit from large-scale manufacturing, global stockpiling experience, and established cold-chain logistics, and Soligenix's thermostable advantage, while technically valid, may not overcome incumbent inertia or procurement preferences for proven efficacy in large outbreaks, especially without Phase 3 human data to validate the 100% NHP protection claim in real-world settings.

The discontinuation of the FLASH2 HyBryte™ trial for futility in April 2026 represents a material setback, as the Data Monitoring Committee's recommendation to halt the study due to lack of efficacy signal—despite 18 weeks of treatment—directly contradicts the earlier Phase 3 FLASH trial's 49% response rate and undermines the core thesis for HyBryte™ as a near-term commercial asset, especially since the company explicitly stated it will analyze data to determine why the study failed, raising concerns about patient heterogeneity, dosing adequacy, or diminishing returns with prolonged exposure, and casting doubt on the validity of prior efficacy signals in the absence of a confirmed mechanism for the discrepancy between studies.
Soligenix's financial runway is increasingly precarious, with cash declining from $7.9 million at December 31, 2025 to $6.0 million by March 31, 2026, reflecting a quarterly burn rate of approximately $1.9 million, and while management claims runway into Q2 2027, this assumes no further setbacks and ignores the likelihood of increased spending to advance SGX945 into Phase 2 or pursue M&A; the absence of any revenue streams—confirmed in both the March 31, 2026 and December 31, 2025 financial updates—means the company remains entirely dependent on external financing, which may be unavailable on acceptable terms given the HyBryte™ failure and the high-risk nature of its biodefense and rare disease pipeline, increasing the probability of a dilutive financing event or forced asset sale.
The Behçet's Disease program, while buoyed by orphan designations, faces significant commercialization hurdles: SGX945 has only demonstrated biological efficacy in a tiny Phase 2a pilot of 8 patients, with no placebo-controlled Phase 2 data yet generated, and the planned H2 2026 trial is still contingent on completing formulation work for home-use administration—a technical risk that has not been de-risked—while the global market estimate of $200 million annually assumes broad uptake in a disease where current therapy (apremilast) already fails due to tolerability issues and chronic use requirements, and there is no guarantee that dusquetide's intermittent dosing advantage will translate to real-world adherence or payer reimbursement, especially without head-to-head Phase 3 data against the incumbent.
The filovirus vaccine opportunity, despite its scientific merit, remains highly speculative and dependent on unpredictable government funding; while the ThermoVax® platform has shown thermostability and immunogenicity in preclinical models, there is no clinical data for a Bundibugyo-specific vaccine, and advancement requires "adequate funding" per Dr. Lehrer's statement, with no committed BARDA, DTRA, or NIAID contracts mentioned in the news—unlike RiVax® which has historical BARDA support—making near-term milestones uncertain, and the company's Public Health Solutions segment has historically relied on grant funding that is subject to performance requirements and renewal risk, as acknowledged in its risk factors, meaning any delay in securing new awards could stall development indefinitely.
Soligenix faces intense competitive pressures in both its rare disease and vaccine segments: in Behçet's Disease, apremilast (Otezla®) is an established, FDA-approved maintenance therapy with broad physician familiarity and payer coverage, despite its side effects, and new entrants like biosimilars or novel small molecules could emerge before SGX945 completes development; in the vaccine space, existing filovirus candidates (e.g., Merck's Ebola vaccine, Janssen's regimens) benefit from large-scale manufacturing, global stockpiling experience, and established cold-chain logistics, and Soligenix's thermostable advantage, while technically valid, may not overcome incumbent inertia or procurement preferences for proven efficacy in large outbreaks, especially without Phase 3 human data to validate the 100% NHP protection claim in real-world settings.

Product and Service Breakdown of Revenue (2024)

Peer group

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	match	Market Cap	P/E	P/S	Total Debt (Qtr)
1	AMGN	Amgen Inc	primary	211.73 Bn	24.22	5.56	62.75 Bn
2	GILD	Gilead Sciences, Inc.	primary	180.92 Bn	-62.49	5.94	28.66 Bn
3	VRTX	Vertex Pharmaceuticals Inc / Ma	primary	132.16 Bn	30.00	10.50	-
4	REGN	Regeneron Pharmaceuticals, Inc.	primary	82.89 Bn	19.15	5.34	1.99 Bn
5	ARGX	Argenx Se	primary	61.41 Bn	35.80	11.75	-
6	MRNA	Moderna, Inc.	primary	53.99 Bn	-17.13	24.23	0.59 Bn
7	ALNY	Alnylam Pharmaceuticals, Inc.	primary	34.48 Bn	44.51	7.18	-
8	BIIB	Biogen Inc.	primary	31.15 Bn	37.32	3.11	8.09 Bn

Soligenix SNGX

About

Investment Thesis

Segments Breakdown of Revenue (2024)

Product and Service Breakdown of Revenue (2024)

Peer Comparison

Create an account

Sign In

Reset Password